JO3430B1 - مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها - Google Patents

مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها

Info

Publication number
JO3430B1
JO3430B1 JOP/2016/0126A JOP20160126A JO3430B1 JO 3430 B1 JO3430 B1 JO 3430B1 JO P20160126 A JOP20160126 A JO P20160126A JO 3430 B1 JO3430 B1 JO 3430B1
Authority
JO
Jordan
Prior art keywords
span
dir
ltr
sub
preparation
Prior art date
Application number
JOP/2016/0126A
Other languages
English (en)
Inventor
James Edward Paul Davidson
Francoise Perron-Sierra
Agnes Proszenyak
Alain Bruno
Zoltan Szlavik
Attila Paczal
Andras Kotschy
Levente Ondi
Marton Csekei
Olivier Geneste
James Brooke Murray
Zoltan Szabo
I-Jen Chen
Balazs Balint
Szabolcs Sipos
Gabor Radics
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Application granted granted Critical
Publication of JO3430B1 publication Critical patent/JO3430B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات لها الصيغة (<span dir="LTR">I</span>)<span dir="LTR">:</span> حيث تكون <span dir="LTR">R<sub>1</sub></span>، <span dir="LTR">R<sub>2</sub></span>، <span dir="LTR">R<sub>5</sub></span>، <span dir="LTR">R<sub>6</sub></span>، <span dir="LTR">R<sub>7</sub></span>، <span dir="LTR">R<sub>12</sub></span>، <span dir="LTR">X</span>، <span dir="LTR">Y</span>، <span dir="LTR">A</span>، <span dir="LTR">E</span> و<span dir="LTR">n</span> مثلما تم تحديده في الوصف. الأدوية.
JOP/2016/0126A 2015-06-23 2016-06-22 مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها JO3430B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1555747A FR3037956B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
JO3430B1 true JO3430B1 (ar) 2019-10-20

Family

ID=54260901

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2016/0126A JO3430B1 (ar) 2015-06-23 2016-06-22 مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها

Country Status (42)

Country Link
US (1) US10457687B2 (ar)
EP (1) EP3313850B1 (ar)
JP (1) JP6741698B2 (ar)
KR (1) KR102620905B1 (ar)
CN (1) CN107709334B (ar)
AR (1) AR105101A1 (ar)
AU (1) AU2016282837B2 (ar)
CA (1) CA2990089C (ar)
CL (1) CL2017003163A1 (ar)
CO (1) CO2017012830A2 (ar)
CR (2) CR20170590A (ar)
CU (1) CU20170164A7 (ar)
CY (1) CY1120991T1 (ar)
DK (1) DK3313850T3 (ar)
EA (1) EA034587B1 (ar)
EC (1) ECSP17082546A (ar)
ES (1) ES2703997T3 (ar)
FR (1) FR3037956B1 (ar)
GE (2) GEP20207075B (ar)
HK (2) HK1252113B (ar)
HR (1) HRP20181806T1 (ar)
IL (1) IL256191B (ar)
JO (1) JO3430B1 (ar)
LT (1) LT3313850T (ar)
MA (1) MA42232B1 (ar)
MD (1) MD3313850T2 (ar)
MX (1) MX368845B (ar)
MY (1) MY189472A (ar)
PE (1) PE20190111A1 (ar)
PH (1) PH12017502266B1 (ar)
PL (1) PL3313850T3 (ar)
PT (1) PT3313850T (ar)
RS (1) RS57961B1 (ar)
RU (1) RU2747673C2 (ar)
SA (1) SA517390583B1 (ar)
SI (1) SI3313850T1 (ar)
SV (1) SV2017005588A (ar)
TN (1) TN2017000521A1 (ar)
TW (1) TWI631124B (ar)
UA (1) UA123267C2 (ar)
UY (1) UY36733A (ar)
WO (1) WO2016207226A1 (ar)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
MX385115B (es) * 2017-01-06 2025-03-14 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta.
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
IL271475B2 (en) 2017-06-22 2023-09-01 Servier Lab Combination of mcl-1 inhibitor and standard medical treatment for hematological cancer, uses and pharmaceutical preparations
CR20200124A (es) 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
AU2018317828A1 (en) * 2017-08-15 2020-04-02 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
CN110964034B (zh) * 2018-09-29 2022-04-12 江苏恒瑞医药股份有限公司 嘧啶并噻吩类衍生物、其制备方法及其在医药上的应用
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
CN111187277B (zh) * 2018-11-14 2022-04-12 江苏恒瑞医药股份有限公司 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
CN112457308B (zh) 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96531A (en) * 1989-12-11 1995-08-31 Univ Princeton History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them)
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
US20070213305A1 (en) * 2005-11-02 2007-09-13 Cytovia, Inc. N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2009241469B2 (en) * 2008-04-30 2015-05-07 National Health Research Institutes Fused bicyclic pyrimidine compounds as Aurora kinase inhibitors
WO2012044993A1 (en) * 2010-09-30 2012-04-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds, pharmaceutical compositions, and methods of treating or preventing neurodegenerative diseases or disorders
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
KR101591153B1 (ko) * 2010-12-20 2016-02-02 그렌마크 파머수티칼스 에스. 아. Trpa1 길항제로서의 2-아미노-4-아릴티아졸 화합물
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20150307532A1 (en) 2012-11-20 2015-10-29 The Royal Institution For The Advancement Of Learning/Mcgill University Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) * 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
KR20180015261A (ko) 2018-02-12
GEAP201914679A (en) 2019-11-11
LT3313850T (lt) 2018-11-26
CL2017003163A1 (es) 2018-06-15
RU2018102372A (ru) 2019-07-23
PH12017502266B1 (en) 2021-01-13
TWI631124B (zh) 2018-08-01
JP2018522856A (ja) 2018-08-16
US20190031675A1 (en) 2019-01-31
CA2990089A1 (en) 2016-12-29
HK1250234A1 (zh) 2018-12-07
CN107709334B (zh) 2021-04-13
SI3313850T1 (sl) 2019-01-31
RU2747673C2 (ru) 2021-05-12
HK1252113A1 (en) 2019-05-17
MX368845B (es) 2019-10-18
MA42232B1 (fr) 2018-11-30
RS57961B1 (sr) 2019-01-31
CO2017012830A2 (es) 2018-03-28
IL256191B (en) 2020-03-31
BR112017027645A2 (pt) 2018-08-28
HK1252113B (en) 2020-01-10
TN2017000521A1 (en) 2019-04-12
KR102620905B1 (ko) 2024-01-04
UY36733A (es) 2016-12-30
PH12017502266A1 (en) 2018-06-11
FR3037956B1 (fr) 2017-08-04
MX2017016996A (es) 2018-08-23
TW201712018A (zh) 2017-04-01
CY1120991T1 (el) 2019-12-11
GEP20207075B (en) 2020-03-10
EP3313850A1 (en) 2018-05-02
AR105101A1 (es) 2017-09-06
WO2016207226A1 (en) 2016-12-29
EA034587B1 (ru) 2020-02-25
ES2703997T3 (es) 2019-03-13
SA517390583B1 (ar) 2022-02-20
EP3313850B1 (en) 2018-10-03
CR20170571A (es) 2018-02-20
AU2016282837B2 (en) 2020-05-28
SV2017005588A (es) 2018-06-01
DK3313850T3 (en) 2019-01-28
CN107709334A (zh) 2018-02-16
RU2018102372A3 (ar) 2019-11-06
FR3037956A1 (ar) 2016-12-30
MA42232A (fr) 2016-12-29
HRP20181806T1 (hr) 2018-12-28
MD3313850T2 (ro) 2019-02-28
CU20170164A7 (es) 2018-05-08
PL3313850T3 (pl) 2019-04-30
UA123267C2 (uk) 2021-03-10
CA2990089C (en) 2020-11-03
PE20190111A1 (es) 2019-01-15
EA201890123A1 (ru) 2018-05-31
PT3313850T (pt) 2018-11-29
JP6741698B2 (ja) 2020-08-19
MY189472A (en) 2022-02-16
NZ738459A (en) 2024-05-31
US10457687B2 (en) 2019-10-29
ECSP17082546A (es) 2018-02-28
IL256191A (en) 2018-02-28
AU2016282837A1 (en) 2018-01-18
CR20170590A (es) 2018-02-26

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
SA517390583B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
JO3807B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
TN2017000524A1 (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
EA201692280A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX376028B (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
MX2017014035A (es) Formas solidas novedosas.
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
EA201690390A1 (ru) Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте
EA201890532A1 (ru) Новые аннелированные бензамиды
EA201890534A1 (ru) Новые аннелированные феноксиацетамиды
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
PH12015502632A1 (en) Cxcr7 receptor modulators
PH12019500822A1 (en) Crystalline forms of eravacycline
JO3742B1 (ar) مركب بيرانو داي بيريدين